3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
4
Carcinoma, Renal Cell
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Castration-resistant Prostate Cancer
2
Urologic Neoplasms
1
Stomach Neoplasms
1
Osteosarcoma
1
Lymphatic Metastasis
1
Ependymoma
1
Colonic Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Breast Neoplasms
1
Bone Neoplasms
1
Adenocarcinoma
1
Interventions
Oxaliplatin
32
Fluorouracil
24
Gemcitabine
23
Leucovorin
19
Docetaxel
19
pembrolizumab
17
Capecitabine
15
Radiotherapy
14
Irinotecan
13
Cisplatin
11
Bevacizumab
11
Nivolumab
8
130-nm albumin-bound paclitaxel
8
Trastuzumab
7
Erlotinib Hydrochloride
7
Cyclophosphamide
7
Albumin-Bound Paclitaxel
7
Radiosurgery
6
Paclitaxel
6
Taxes
5
S 1 (combination)
5
Metformin
5
Carboplatin
5
Blood Specimen Collection
5
Sunitinib
4
Sorafenib
4
Pemetrexed
4
Esophagectomy
4
Chemoradiotherapy
4
Cetuximab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adenocarcinoma
×
Metastasectomy
×
Clear all
NCT06121700
2023-11-08
Miracle-G
Fudan University
Phase 2
Recruiting
55 enrolled